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Background
Self-amplifying RNAs (replicons) of positive-strand viruses
such as alphaviruses are potentially safe and useful vectors
for delivering vaccine antigens. Recombinant alphavirus
replicon particles (VRP), carrying the self-amplifying RNA,
protects rhesus macaques against SHIVSF162P4 challenge
when used in a prime-boost regimen.
Methods
Novartis VRPs are being further tested using a current
state-of-the art physiologically relevant low-dose SIV
virus swarm challenge. To meet the need for the large
numbers of VRP an alphavirus packaging cell line (PCL)
was used for VRP production. We manufactured, charac-
terized, stability and small animal potency tested VRPs
expressing SIVmac239 envelope (env) and gag/pol fusion
proteins (VRP Env, VRP Gag/pol, respectively) for a large
macaque vaccine study. Macaques were co-immunized
with both VRPs thrice followed by two boosts with an
MF59-adjuvanted CHO cell-derived SIVmac239 trimeric
env protein.
Results
Here we show that three VRP priming immunizations
induce both env- and gag-specific IgG and T-cell
responses, robustly. Binding env-specific IgG titers were
demonstrable in 100% of animals with titers ranging from
~10000-400000. T-cell responses to env and gag devel-
oped in 80% of macaques (env-specific range ~100-1200,
gag-specific range ~100-700 SFC/106 PBMCs) when
assayed using an IFNg T-cell ELISpot. The MF59-adju-
vanted Env protein by itself was also robustly immuno-
genic with Env-specific IgG titers and T-cell responses
ranging from ~100000-1700000 (100% response) and
~100-1000 SFC/106 PBMCs (90% response), respectively.
No adverse events were reported upon immunization of
either the VRP or the MF59-adjuvanted env vaccines.
Conclusion
We provide further details on the currently ongoing effi-
cacy evaluations of these safe and immunogenic vaccines
in a prime-boost regimen using repeated low-dose het-
erologous SIVsmE660 intra-rectal challenges. NIH Grant
N01-AI-50007.
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